{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:15:31Z","timestamp":1778681731470,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:00:00Z","timestamp":1768694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:00:00Z","timestamp":1768694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The CD3xCD20 bispecific antibody epcoritamab demonstrated deep, durable responses with manageable safety in relapsed\/refractory (R\/R) follicular lymphoma (FL) in EPCORE NHL-3 (phase 1\/2; NCT04542824). This analysis evaluated 3-year follow-up outcomes in Japanese patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with CD20\u2009+\u2009FL and\u2009\u2265\u20092 prior lines of therapy (LOTs) received subcutaneous epcoritamab (0.16\/0.8-mg step-up doses; 48-mg full doses) until disease progression or death. The primary endpoint was overall response rate (ORR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-one patients received epcoritamab (median age: 65\u00a0years; median prior LOTs:\u00a04; 57.1% double refractory; 57.1% progressed within 24\u00a0months of any first-line treatment). At a median follow-up of 35\u00a0months, the ORR was 95.2% and the complete response (CR) rate was 76.2%. Median duration of response, duration of\u00a0CR, progression-free survival, and overall survival were not reached. At 3\u00a0years, 66.7% and 93.3% of complete responders remained progression-free and alive, respectively. Minimal residual disease negativity was achieved in 88.9% (16\/18) of evaluable patients. Common treatment-emergent adverse events included cytokine release syndrome (90.5%) and injection-site reaction (71.4%), all predominantly grade 1\u20132 and occurring in early treatment cycles, and none fatal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Epcoritamab monotherapy provided durable long-term remission with favorable safety in Japanese patients with R\/R FL over 3\u00a0years of follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12185-025-04139-1","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T09:31:43Z","timestamp":1768728703000},"page":"696-707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Three-year follow-up of epcoritamab therapy in Japanese patients with relapsed\/refractory follicular lymphoma in EPCORE NHL-3"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-8057","authenticated-orcid":false,"given":"Koji","family":"Izutsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daigo","family":"Akahane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Toubai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Momoko","family":"Nishikori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kumode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youko","family":"Suehiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ishitsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poliana","family":"Patah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara D\u2019Angelo","family":"M\u00e5nsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Favaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,18]]},"reference":[{"key":"4139_CR1","volume-title":"Relapsed and refractory follicular lymphoma","author":"D Singh","year":"2023","unstructured":"Singh D, Singh A, Mukkamalla SKR. Relapsed and refractory follicular lymphoma. Treasure Island, FL, USA: StatPearls Publishing; 2023."},{"issue":"11","key":"4139_CR2","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1002\/cam4.1805","volume":"7","author":"R Muto","year":"2018","unstructured":"Muto R, Miyoshi H, Sato K, Furuta T, Muta H, Kawamoto K, et al. Epidemiology and secular trends of malignant lymphoma in Japan: analysis of 9426 cases according to the World Health Organization classification. Cancer Med. 2018;7(11):5843\u201358.","journal-title":"Cancer Med"},{"key":"4139_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000745","volume":"6","author":"G Salles","year":"2022","unstructured":"Salles G, Schuster SJ, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, et al. A retrospective cohort study of treatment outcomes of adult patients with relapsed or refractory follicular lymphoma (ReCORD-FL). HemaSphere. 2022;6:e745.","journal-title":"HemaSphere"},{"key":"4139_CR4","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1182\/bloodadvances.2021004535","volume":"8","author":"JE Haydu","year":"2024","unstructured":"Haydu JE, Abramson JS. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas. Blood Adv. 2024;8:4700\u201310.","journal-title":"Blood Adv"},{"key":"4139_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood-2016-07-729954","volume":"129","author":"K Krysiak","year":"2017","unstructured":"Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, et al. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood. 2017;129:473\u201383.","journal-title":"Blood"},{"key":"4139_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/14737140.2023.2171994","volume":"23","author":"ML Palomba","year":"2023","unstructured":"Palomba ML, Ghione P, Patel AR, Nahas M, Beygi S, Hatswell AJ, et al. A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma. Expert Rev Anticancer Ther. 2023;23:199\u2013206.","journal-title":"Expert Rev Anticancer Ther"},{"key":"4139_CR7","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516\u201322.","journal-title":"J Clin Oncol"},{"key":"4139_CR8","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1016\/S2352-3026(22)00033-3","volume":"9","author":"C Casulo","year":"2022","unstructured":"Casulo C, Larson MC, Lunde JJ, Habermann TM, Lossos IS, Wang Y, et al. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol. 2022;9:e289-300.","journal-title":"Lancet Haematol"},{"key":"4139_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28:325\u201332.","journal-title":"Nat Med"},{"key":"4139_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23:91\u2013103.","journal-title":"Lancet Oncol"},{"key":"4139_CR11","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","volume":"30","author":"F Morschhauser","year":"2024","unstructured":"Morschhauser F, Dahiya S, Palomba ML, Garcia-Sancho AM, Reguera-Ortega JL, Kuruvilla J, et al. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med. 2024;30:2199\u2013207.","journal-title":"Nat Med"},{"key":"4139_CR12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","volume":"143","author":"SS Neelapu","year":"2024","unstructured":"Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024;143:496\u2013506.","journal-title":"Blood"},{"key":"4139_CR13","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2024.012","volume":"16","author":"U Testa","year":"2024","unstructured":"Testa U, D\u2019Al\u00f2 F, Pelosi E, Castelli G, Leone G. CAR-T cell therapy for follicular lymphomas. Mediterr J Hematol Infect Dis. 2024;16:e2024012.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"4139_CR14","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","volume":"11","author":"KM Linton","year":"2024","unstructured":"Linton KM, Vitolo U, Jurczak W, Lugtenburg PJ, Gyan E, Sureda A, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024;11:e593-605.","journal-title":"Lancet Haematol"},{"key":"4139_CR15","unstructured":"EPKINLY (epcoritamab-bysp) [prescribing information]. Tokyo, Japan: AbbVie GK, Genmab K.K.; 2025."},{"key":"4139_CR16","unstructured":"EPKINLY (epcoritamab-bysp) [prescribing information]. Plainsboro, NJ, USA: Genmab US, Inc.; 2024."},{"key":"4139_CR17","unstructured":"TEPKINLY (epcoritamab) [summary of product characteristics]. Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co. KG; 2024."},{"issue":"10","key":"4139_CR18","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1080\/10428194.2025.2525983","volume":"66","author":"K Izutsu","year":"2025","unstructured":"Izutsu K, Akahane D, Toubai T, Saito T, Mishima Y, Fujisaki T, et al. Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial. Leuk Lymphoma. 2025;66(10):1913\u201321.","journal-title":"Leuk Lymphoma"},{"key":"4139_CR19","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"4139_CR20","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S. Department of Health and Human Services. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Published November 27, 2017. Accessed May 26, 2025."},{"key":"4139_CR21","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","volume":"26","author":"B Coiffier","year":"2008","unstructured":"Coiffier B, Altman A, Pui C-H, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26:2767\u201378.","journal-title":"J Clin Oncol"},{"key":"4139_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"4139_CR23","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s10147-025-02788-0","volume":"30","author":"K Izutsu","year":"2025","unstructured":"Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, et al. Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial. Int J Clin Oncol. 2025;30(8):1631\u201340.","journal-title":"Int J Clin Oncol"},{"key":"4139_CR24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s12185-025-03922-4","volume":"121","author":"K Izutsu","year":"2025","unstructured":"Izutsu K, Fukuhara N. JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma-1. Follicular lymphoma (FL). Int J Hematol. 2025;121:577\u201385.","journal-title":"Int J Hematol"},{"issue":"Suppl 1","key":"4139_CR25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205671","volume":"144","author":"G Iacoboni","year":"2024","unstructured":"Iacoboni G, Kyvsgaard ER, Garces VN, Russler-Germain DA, Garc\u00eda-Sancho AM, Thompson PA, et al. Impact of prior bendamustine exposure on bispecific antibody treatment outcomes in patients with relapsed\/refractory follicular lymphoma. Blood. 2024;144(Suppl 1):3009.","journal-title":"Blood"},{"key":"4139_CR26","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23:1055\u201365.","journal-title":"Lancet Oncol"},{"key":"4139_CR27","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","volume":"38","author":"C Thieblemont","year":"2024","unstructured":"Thieblemont C, Karimi YH, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024;38:2653\u201362.","journal-title":"Leukemia"},{"key":"4139_CR28","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834\u201340.","journal-title":"Blood"},{"key":"4139_CR29","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1007\/s13760-024-02580-3","volume":"124","author":"H Yokota","year":"2024","unstructured":"Yokota H, Hoshida Y, Hirakawa K, Miwa T, Yamada T. Progressive multifocal leukoencephalopathy following obinutuzumab and bendamustine therapy for follicular lymphoma: case report and literature review. Acta Neurol Belg. 2024;124:2085\u20139.","journal-title":"Acta Neurol Belg"},{"key":"4139_CR30","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/ejh.13751","volume":"108","author":"PT Diamantopoulos","year":"2022","unstructured":"Diamantopoulos PT, Kalopisis K, Tsatsou A, Efthymiou A, Giannakopoulou N, Hatzidavid S, et al. Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies. Eur J Haematol. 2022;108:359\u201368.","journal-title":"Eur J Haematol"},{"key":"4139_CR31","unstructured":"Abreu M, Patel CB, Patel K, Khawaja F, Tummala S. Progressive multifocal leukoencephalopathy in chimeric antigen receptor t-cell therapy recipients: a case study. J Adv Pract Oncol. Published online May 6, 2025."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04139-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04139-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04139-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:30:11Z","timestamp":1778679011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04139-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,18]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4139"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04139-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,18]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Koji Izutsu has received honoraria and fees from Janssen and Ono Pharmaceutical; and has received research funding from AbbVie, BeiGene, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Genmab, Incyte Biosciences, Janssen, Novartis, and Yakult. Daigo Akahane has nothing to disclose. Tomomi Toubai has received research funding from AbbVie and IQVIA. Toko Saito has received research funding from AbbVie, AstraZeneca, IQVIA, Janssen, Meiji Seika Pharma. Co, and Nippon Shinyaku. Yuko Mishima has received honoraria and fees from Chugai and Roche; and has received scholarship endowments\/academic research funding from Bristol Myers Squibb, Eisai, and Takeda. Tomoaki Fujisaki has nothing to disclose. Momoko Nishikori has received honoraria\/fees from Chugai and Genmab; and has received research funding from SymBio. Takahiro Kumode has received honoraria and fees from AbbVie, AstraZeneca, BeiGene, Genmab, Janssen, and Ono Pharmaceutical. Youko Suehiro has received research funding from AbbVie, Amgen, Chugai, Genmab, Incyte, Kyowa Kirin, Otsuka, and All Japan Pharma. Kenji Ishitsuka has nothing to disclose. Poliana Patah is an employee of and stockholder in AbbVie. Ami Takahashi, Barabara D\u2019Angelo M\u00e5nsson, and Elena Favaro are employees of and stockholders in Genmab. Noriko Fukuhara is an editor of the\n                      International Journal of Hematology\n                      and; has received honoraria and fees from Bristol Myers Squibb, Chugai, HUYA, and SymBio; and has received research funding from AbbVie, Bayer, Bristol Myers Squibb, Chordia, Chugai, Genmab, Incyte, Kyowa Kirin, Loxo Oncology, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval for this study protocol was obtained from an independent ethics committee prior to trial initiation. The trial was conducted according to International Council for Harmonisation Good Clinical Practice (GCP) E6(R2) guidelines, local Japan GCP guidelines, the principles of the Declaration of Helsinki, and all applicable regulatory requirements. Written informed consent was obtained from all patients prior to trial enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}